PCM
OVID icon

Prelude Capital Management’s Ovid Therapeutics OVID Stock Holding History

Prelude Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,951
Closed -$24.3K – 1449
2026
Q1 		$24.3K Buy
+10,951
New +$19.6K ﹤0.01% 1156
2024
Q2 		– Sell
-25,555
Closed -$77.9K – 1417
2024
Q1 		$77.9K Buy
+25,555
New +$85.5K ﹤0.01% 1225

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Prelude Capital Management's OVID Position: Q2 2026 in Review

Prelude Capital Management sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 10,951 shares — an estimated $24.3K sold.

Prelude Capital Management first reported a position in OVID in Q1 2024 and held it in 2 quarters. The position peaked at $77.9K in Q1 2024. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Prelude Capital Management reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 10,951 Ovid Therapeutics shares in Q2 2026, an estimated $24.3K.
  • Prelude Capital Management first reported a position in Ovid Therapeutics in Q1 2024 and held it in 2 quarters.
  • Prelude Capital Management's Ovid Therapeutics position peaked at $77.9K in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.